Published in
American Society of Hematology, Blood, 5(133), p. 494-497, 2019
DOI: 10.1182/blood-2018-03-839688
Links
Tools
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
Journal article published in 2019 by
Anton W. Langerak 
,
Matthias Ritgen,
Valentin Goede,
Sandra Robrecht,
Jasmin Bahlo,
Kirsten Fischer,
Michael Steurer,
Marek Trněný ,
Stephen P. Mulligan,
Ulrich J. M. Mey,
Kerstin Trunzer ,
Günter Fingerle-Rowson,
Kathryn Humphrey,
Stephan Stilgenbauer,
Sebastian Böttcher
and other authors.
,
Matthias Ritgen,
Valentin Goede,
Sandra Robrecht,
Jasmin Bahlo,
Kirsten Fischer,
Michael Steurer,
Marek Trněný ,
Stephen P. Mulligan,
Ulrich J. M. Mey,
Kerstin Trunzer ,
Günter Fingerle-Rowson,
Kathryn Humphrey,
Stephan Stilgenbauer,
Sebastian Böttcher
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 